ANNX

Annexon Inc

4.01

Oct 29 • 3:59 PM ET -0.03 (-0.74%)

4.01

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: DNTH OMER IFRX ARGX IMVT EYPT PRTA KOD AKTX RLYB

| Held by: XBI VTI IWM VXF IWO IBB FESM VTWO SCHA DFAS

Scroll to Statements

Index	RUT
Market Cap	760.21M
Enterprise Value	575.62M
Income	-202.67M
Sales	0.00M
Book/sh	1.07
Cash/sh	1.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	96
IPO	Jul 24, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.76
P/C	3.63
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.53
Current Ratio	5.53
Debt/Eq	0.13
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	-1.15
EPS next Y	-0.99
EPS next Q	-0.28
EPS this Y	21.51%
EPS next Y	5.96%
EPS next 5Y	46.37%
EPS past 3/5Y	19.69% 20.17%
Sales past 3/5Y	- -
EPS Y/Y TTM	10.96%
Sales Y/Y TTM	-
EPS Q/Q	19.92%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-17.25% -

Insider Own	13.00%
Insider Trans	2.70%
Inst Own	89.78%
Inst Trans	16.83%
ROA	-79.38%
ROE	-105.26%
ROIC	-97.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.23%
SMA50	-5.13%
SMA200	-23.37%
Trades

Shs Outstand	174.60M
Shs Float	164.93M
Short Float	19.18%
Short Ratio	10.11
Short Interest	31.63M
52W High	7.18 -44.15%
52W Low	2.54 57.87%
Volatility	5.92% 6.35%
ATR (14)	0.25
RSI (14)	51.23
Beta	1.43
Rel Volume	1.05
Avg Volume	3.13M
Volume	3,284,770

Perf Week	5.25%
Perf Month	-5.20%
Perf Quarter	-21.30%
Perf Half Y	-31.69%
Perf YTD	-20.12%
Perf Year	25.71%
Perf 3Y	92.79%
Perf 5Y	-75.41%
Perf 10Y	-
Recom	1.36
Target Price	17.00
Prev Close	4.04
Price	4.01
Change %	-0.74%

Consensus

Strong Buy

Avg. Price Target

$17.00

Implied Upside

+323.9%

Analysts12incl. previous ratings

Rating Distribution10 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 13, 2026	Upgrade	CCitizens	Mkt Underperform → Mkt Perform
Jul 21, 2026	Initiated	CCitizens	Mkt Underperform	$3	-25.2%
May 12, 2026	Initiated	GGoldman	Neutral	$7	+74.6%
Dec 23, 2025	Initiated	CChardan Capital Markets	Buy	$16	+299.0%
Mar 01, 2024	Upgrade	JJP Morgan	Neutral → Overweight	$11	+174.3%
Dec 21, 2023	Upgrade	BBofA Securities	Neutral → Buy	$4 → $6	+49.6%
Oct 30, 2023	Initiated	WWells Fargo	Overweight	$11	+174.3%
May 26, 2023	Downgrade	BBofA Securities	Buy → Neutral	$8 → $3	-25.2%
May 25, 2023	Downgrade	JJP Morgan	Overweight → Neutral	$19 → $9	+124.4%
Sep 16, 2022	Initiated	JJefferies	Buy	$12	+199.3%
Sep 09, 2022	Initiated	BBTIG Research	Buy	$15	+274.1%
Nov 30, 2021	Initiated	HH.C. Wainwright	Buy	$40	+897.5%
Sep 23, 2021	Initiated	CCantor Fitzgerald	Overweight	$40	+897.5%
Jan 26, 2021	Initiated	NNeedham	Buy	$37	+822.7%
Aug 18, 2020	Initiated	JJP Morgan	Overweight	$33	+722.9%
Aug 18, 2020	Initiated	CCowen	Outperform
Aug 18, 2020	Initiated	BBofA Securities	Buy	$33	+722.9%

Oct-28-26 08:00AM	Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial (GlobeNewswire) +7.45%
Oct-16-26 05:34PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.28% +17.60%
Sep-24-26 08:00AM	Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting (GlobeNewswire)
Sep-16-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Sep-02-26 08:00AM	Annexon to Participate in Upcoming September Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Aug-17-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-26 07:33AM	Annexon shares fall as second-quarter loss exceeds Wall Street forecasts (InvestorsHub)
06:05AM	Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones (GlobeNewswire)
06:00AM	Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study (GlobeNewswire)
Aug-10-26 04:05PM	Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors (GlobeNewswire)
Aug-06-26 08:00AM	Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week (GlobeNewswire)
Jul-30-26 04:01PM	Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance (GlobeNewswire) +8.44%
Jul-16-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.38%
Jul-14-26 04:05PM	Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 (GlobeNewswire) +17.12%
Jun-16-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.29%
08:00AM	Loading…
May-27-26 08:00AM	Annexon to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-18-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-26 04:01PM	Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire)
May-06-26 08:00AM	Annexon to Present at the Bank of America Securities Health Care Conference 2026 (GlobeNewswire)
Apr-08-26 04:05PM	Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-26 08:00PM	Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High? (Quartz)
Mar-30-26 04:01PM	Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +11.69%
Mar-16-26 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 05:48AM	Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference (MarketBeat)
Feb-24-26 08:00AM	Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-17-26 08:00AM	Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy (GlobeNewswire)
Jan-16-26 05:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-26 05:10PM	Annexon Maps Pivotal 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead (MarketBeat) +7.92% -7.78%
Jan-12-26 07:00AM	Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 (GlobeNewswire) +5.90%
Jan-08-26 08:00AM	Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barre Syndrome (GlobeNewswire)
04:05PM	Loading…
Jan-07-26 04:05PM	Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.43%
Dec-23-25 08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-18-25 01:14AM	Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development (Insider Monkey)
Dec-16-25 07:31PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-25 01:26AM	Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement (Insider Monkey)
Nov-14-25 04:01PM	Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million (GlobeNewswire) +11.44%
Nov-12-25 10:55PM	Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.63%
04:12PM	Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-10-25 04:05PM	Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire)
Sep-30-25 11:41AM	Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition (Insider Monkey)
Aug-27-25 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.81%
Aug-14-25 04:05PM	Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -8.46%
Aug-11-25 07:29AM	Annexon announces EMA selection of vonaprument for PDC pilot participation (Pharmaceutical Business Review)
Aug-07-25 04:30PM	Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy (GlobeNewswire)
Jul-24-25 07:00AM	Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
Jun-18-25 04:05PM	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) (GlobeNewswire)
May-29-25 04:05PM	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.39% -6.42%
May-19-25 04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-16-25 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
May-12-25 08:00AM	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +10.62%
May-09-25 05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire) -5.88%
05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire)
May-07-25 08:00AM	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress (GlobeNewswire)
Apr-16-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-15-25 07:12AM	Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (Seeking Alpha)
Apr-10-25 09:24AM	Why Annexon Inc. (ANNX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 03:20PM	Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder (Benzinga) -7.79%
Apr-08-25 04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -5.52%
04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Apr-03-25 06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barre Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -6.63% -7.65%
06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77% -9.09%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-03-25 08:00AM	Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -9.47%
Feb-26-25 04:05PM	Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Love Douglas	PRESIDENT AND CEO	Sep 24 '26	Buy	3.83	26,065	99,829	390,476	Sep 25 04:15 PM
WIGGANS THOMAS G	Former Director	Aug 13 '26	Proposed Sale	5.30	2,000	10,596		Aug 13 03:34 PM
WIGGANS THOMAS G	Former Director	Jul 15 '26	Proposed Sale	6.32	2,000	12,630		Jul 15 04:19 PM
WIGGANS THOMAS G	Former Director	Jul 14 '26	Proposed Sale	5.61	1,000	5,605		Jul 14 01:56 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jun 11 '26	Option Exercise	1.85	30,646	56,698	184,807	Jun 15 04:15 PM
Satter Muneer A	Director	May 28 '26	Buy	5.41	613,497	3,319,019	10,342,134	May 29 05:21 PM
Carson William H.	Director	May 11 '26	Buy	5.78	8,000	46,240	78,405	May 13 04:30 PM
Carson William H.	Director	Apr 10 '26	Buy	6.20	8,000	49,600	70,405	Apr 14 04:16 PM
Carson William H.	Director	Mar 10 '26	Buy	5.67	8,000	45,360	62,405	Mar 12 04:31 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Mar 02 '26	Sale	5.43	5,820	31,603	123,582	Mar 04 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Mar 02 '26	Sale	5.42	4,339	23,517	182,625	Mar 04 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Mar 02 '26	Sale	5.42	5,566	30,168	154,161	Mar 04 04:30 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Mar 02 '26	Sale	5.43	5,894	32,004	180,093	Mar 04 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Mar 02 '26	Sale	5.42	5,565	30,162	170,700	Mar 04 04:30 PM
Yednock Ted	Officer	Mar 02 '26	Proposed Sale	5.42	5,566	30,181		Mar 02 05:05 PM
ARTIS DEAN RICHARD	Officer	Mar 02 '26	Proposed Sale	5.43	5,894	31,980		Mar 02 04:41 PM
Overdorf Michael	Officer	Mar 02 '26	Proposed Sale	5.42	4,339	23,530		Mar 02 04:16 PM
Dananberg Jamie	Officer	Mar 02 '26	Proposed Sale	5.43	5,820	31,579		Mar 02 04:05 PM
Lew Jennifer	Officer	Mar 02 '26	Proposed Sale	5.42	5,565	30,178		Mar 02 04:02 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '26	Sale	5.10	5,290	26,979	73,152	Feb 20 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	5.11	7,851	40,119	113,765	Feb 20 04:30 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '26	Sale	5.10	5,290	26,979	123,487	Feb 20 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '26	Sale	5.11	7,857	40,149	97,227	Feb 20 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '26	Sale	5.10	6,225	31,747	124,464	Feb 20 04:30 PM
Lew Jennifer	Officer	Feb 18 '26	Proposed Sale	5.11	7,851	40,119		Feb 18 03:39 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '26	Proposed Sale	5.10	5,290	26,990		Feb 18 03:38 PM
Yednock Ted	Officer	Feb 18 '26	Proposed Sale	5.11	7,857	40,122		Feb 18 03:29 PM
Overdorf Michael	Officer	Feb 18 '26	Proposed Sale	5.10	6,225	31,764		Feb 18 03:20 PM
Dananberg Jamie	Officer	Feb 18 '26	Proposed Sale	5.10	5,290	26,990		Feb 18 03:11 PM
Carson William H.	Director	Dec 30 '25	Buy	5.02	4,115	20,657	54,405	Jan 02 04:30 PM
Choi Jung	Director	Dec 01 '25	Buy	4.19	33,000	138,270	33,000	Dec 03 04:30 PM
Carson William H.	Director	Dec 01 '25	Buy	4.47	4,115	18,394	50,290	Dec 03 04:30 PM
Satter Muneer A	Director	Nov 21 '25	Buy	4.28	422,613	1,808,784	9,728,637	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 20 '25	Buy	4.48	400,000	1,792,000	9,306,024	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 19 '25	Buy	3.94	500,000	1,970,000	8,906,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 18 '25	Buy	3.18	500,000	1,590,000	8,406,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 17 '25	Buy	2.99	500,000	1,495,000	7,906,024	Nov 19 09:00 PM
Carson William H.	Director	Oct 30 '25	Buy	3.17	4,115	13,045	46,175	Oct 31 04:15 PM

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

J.D.Mr. Douglas E. Love Esq.

Executive VPMs. Jennifer Lew CPA

Executive VPDr. Ted Yednock Ph.D.

Chief Scientific Officer & Executive VPDr. Dean R. Artis Ph.D.

Chief Human Resources OfficerMs. Linda A. Fitzpatrick

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANNX

Annexon Inc

Upgrade your Finviz experience